# 378
I'm not sure if this is simply product promotion from the manufacturer, or the telegraphing of the government's intentions regarding the distribution of a pre-pandemic vaccine. Frankly, the story can be read two ways. The vaccine as a preventative, or used `in the event that an influenza pandemic affects Australia'.
What isn't clear from this article is if they are talking shots for everyone within six months from now, or within six months of the start of a pandemic. A trivial point, perhaps, but it does make a difference.
In any event, the news of a new vaccine, developed by GSL has been all over the news the past few hours.
A pre-pandemic vaccine, based on an older strain of the H5N1 virus may, or may not provide immunity. It is hoped, however, that even if it doesn't prevent infection, it could reduce the severity of any illness.
Every Australian could receive vaccination soon
By Sue Dunlevy
January 31, 2007 02:00am
Article from:
EVERY Australian could get vaccine protection against the deadly bird flu virus within six months after Australian drug company CSL announced it had developed a vaccine that prevents the disease.
Trials just completed show two 30mg doses of the CSL vaccine delivered three weeks apart produce a strong immune response to the H5N1 bird flu virus in adults aged 18 to 65.
The company has asked Australia's drug safety watchdog the Therapeutic Goods Administration to register the vaccine so that it can be used by the general population.
It says it can manufacture enough vaccine to protect the entire Australian population within six months.
The TGA said it is dealing with the request "expeditiously in recognition of the potential importance of a pandemic vaccine".
The drug company says trials show the vaccine is safe and well tolerated. "CSL is delighted to reassure the community the Australian Government will be able to respond with CSL's vaccine in the event that an influenza pandemic affects Australia," CSL chief scientific officer Andrew Cuthbertson said.
Australia, with just over 20 million inhabitants, could probably produce enough vaccine, and distribute it in a reasonably short period of time. With 1/15th the population of the United States, the logistics of a nationwide vaccination program, while not insignificant, would likely be manageable.
Some nations, including Switzerland, are investing heavily in a pre-pandemic vaccine. Given the shortage of antiviral medications, and recent concerns over resistant strains of the H5N1 virus developing, it is easy to understand their allure.
